Compounds for enzyme inhibition
AssigneeOnyx Therapeutics, Inc.
InventorsKevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
Life of this patent
Estimating the term…
Abstract
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
Claims10
1-32. (canceled)
A method for the treatment of a disease or condition selected from an immune-related disease, cancer, inflammation, infection, proliferative disease, or neurodegenerative disease, comprising administering a compound having a structure
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.